Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Jan. 21, 2025 (HealthDay News) — For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk classification or treatment decisions, according to a review published online Jan. 21 in the Annals of Internal Medicine<\/em>.<\/p>\n Amir Alishahi Tabriz, M.D., Ph.D., M.P.H., from the Moffitt Cancer Center in Tampa, Florida, and colleagues conducted a systematic review to summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions regarding treatment choice among patients with localized PCa considering first-line treatment. Studies on risk classification and treatment choice after GC testing were independently identified by two investigators.<\/p>\n The researchers identified 10 studies that reported on risk reclassification after GC testing. Very low-risk or low-risk patients with PCa were more likely to have their risk levels classified as the same or lower in observational studies with a low risk for bias (GPS: 100 to 88.1 percent; Decipher: 87.2 to 82.9 percent; Prolaris: 76.9 percent). GC testing with GPS reclassified 34.5 and 29.4 percent of very low-risk and low-risk patients, respectively, to a higher risk category in one randomized study. Treatment decisions after GC testing either remained unchanged or slightly favored active surveillance based on 12 observational studies; however, in analyses from a single randomized trial, fewer choices for active surveillance after GPS testing were seen.<\/p>\n “Although GC tests do not consistently influence risk classification or treatment decisions, the differences observed between observational and randomized studies highlight a need for well-designed trials to explore the role of GC tests in patients with newly diagnosed PCa considering first-line treatment,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n